tetano
Editor, Senior Moderator
Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(1):e196. doi: 10.1212/NXI.0000000000000196. eCollection 2016.
[h=1]Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination.[/h] Lin YC[SUP]1[/SUP], Winokur P[SUP]1[/SUP], Blake A[SUP]1[/SUP], Wu T[SUP]1[/SUP], Manischewitz J[SUP]1[/SUP], King LR[SUP]1[/SUP], Romm E[SUP]1[/SUP], Golding H[SUP]1[/SUP], Bielekova B[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]OBJECTIVE:[/h] The purpose of this study was to assess the potential immunosuppressive role of daclizumab, a humanized monoclonal antibody against the α chain of the interleukin 2 receptor, in vivo, by comparing immune responses to the 2013 seasonal influenza vaccination between patients with multiple sclerosis (MS) on long-term daclizumab therapy and controls.
[h=4]METHODS:[/h] Previously defined subpopulations of adaptive immune cells known to correlate with the immune response to the influenza vaccination were evaluated by 12-color flow cytometry in 23 daclizumab-treated patients with MS and 14 MS or healthy controls before (D0) and 1 day (D1) and 7 days (D7) after administration of the 2013 Afluria vaccine. Neutralizing antibody titers and CD4(+), CD8(+) T cell, B cell, and natural killer cell proliferation to 3 strains of virus contained in the Afluria vaccine were assessed at D0, D7, and 180 days postvaccination.
[h=4]RESULTS:[/h] Daclizumab-treated patients and controls demonstrated comparable, statistically significant expansions of previously defined subpopulations of activated CD8(+) T cells and B cells that characterize the development of effective immune responses to the influenza vaccine, while proliferation of T cells to influenza and control antigens was diminished in the daclizumab cohort. All participants fulfilled FDA criteria for seroconversion or seroprotection in antibody assays.
[h=4]CONCLUSION:[/h] Despite the mild immunosuppressive effects of daclizumab in vivo demonstrated by an increased incidence of infectious complications in clinical trials, patients with MS under daclizumab therapy mount normal antibody responses to influenza vaccinations.
PMID: 26848487 [PubMed] PMCID: PMC4733151 Free PMC Article
[h=1]Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination.[/h] Lin YC[SUP]1[/SUP], Winokur P[SUP]1[/SUP], Blake A[SUP]1[/SUP], Wu T[SUP]1[/SUP], Manischewitz J[SUP]1[/SUP], King LR[SUP]1[/SUP], Romm E[SUP]1[/SUP], Golding H[SUP]1[/SUP], Bielekova B[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]OBJECTIVE:[/h] The purpose of this study was to assess the potential immunosuppressive role of daclizumab, a humanized monoclonal antibody against the α chain of the interleukin 2 receptor, in vivo, by comparing immune responses to the 2013 seasonal influenza vaccination between patients with multiple sclerosis (MS) on long-term daclizumab therapy and controls.
[h=4]METHODS:[/h] Previously defined subpopulations of adaptive immune cells known to correlate with the immune response to the influenza vaccination were evaluated by 12-color flow cytometry in 23 daclizumab-treated patients with MS and 14 MS or healthy controls before (D0) and 1 day (D1) and 7 days (D7) after administration of the 2013 Afluria vaccine. Neutralizing antibody titers and CD4(+), CD8(+) T cell, B cell, and natural killer cell proliferation to 3 strains of virus contained in the Afluria vaccine were assessed at D0, D7, and 180 days postvaccination.
[h=4]RESULTS:[/h] Daclizumab-treated patients and controls demonstrated comparable, statistically significant expansions of previously defined subpopulations of activated CD8(+) T cells and B cells that characterize the development of effective immune responses to the influenza vaccine, while proliferation of T cells to influenza and control antigens was diminished in the daclizumab cohort. All participants fulfilled FDA criteria for seroconversion or seroprotection in antibody assays.
[h=4]CONCLUSION:[/h] Despite the mild immunosuppressive effects of daclizumab in vivo demonstrated by an increased incidence of infectious complications in clinical trials, patients with MS under daclizumab therapy mount normal antibody responses to influenza vaccinations.
PMID: 26848487 [PubMed] PMCID: PMC4733151 Free PMC Article